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Abstract
The Millennium Development Goals (MDGs) made a marked transformation for neglected and vulnerable
communities in the developing countries from the start, but infectious diseases of poverty (IDoPs) continue to
inflict a disproportionate global public health burden with associated consequences, thereby contributing to the
vicious cycle of poverty and inequity. However, the effectiveness and large-scale coverage of artemisinin
combination therapy (ACT) have revolutionized malaria treatment just as the control of lymphatic filariasis (LF) and
onchocerciasis have benefitted from harnessing the broad-spectrum effect of avermectin-based derivatives. The
paradigm shift in therapeutic approach, effected by these two drugs and their impact on community-based
interventions of parasitic diseases plaguing the endemic low- and middle-income countries (LIMCs), led to the
Nobel Prize in Physiology or Medicine in 2015. However, the story would not be complete without mentioning
praziquantel. The huge contribution of this drug in modernizing the control of schistosomiasis and also some
intestinal helminth infections had already shifted the focus from control to potential elimination of this disease.
Together, these new drugs have provided humankind with powerful new tools for the alleviation of infectious
diseases that humans have lived with since time immemorial. These drugs all have broad-spectrum effects, yet they
are very safe and can even be packaged together in various combinations. The strong effect on so many of the
great infectious scourges in the developing countries has not only had a remarkable influence on many endemic
diseases, but also contributed to improving the cost structure of healthcare. Significant benefits include improved
quality of preventive and curative medicine, promotion of community-based interventions, universal health
coverage and the fostering of global partnerships. The laudable progress and benefits achieved are indispensable in
championing, strengthening and moving forward elimination of the IDoPs. However, there is an urgent need for
further innovative, contextual and integrated approaches along with the advent of the Sustainable Development
Goals (SDGs), replacing the MDGs in ensuring global health security, well-being and economic prosperity for all.
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This year's Nobel Prize in Physiology or Medicine,
awarded for the discovery of artemisinin and ivermectin,
was divided between Youyou Tu "for her discoveries
concerning a novel therapy against malaria" and William
C. Campbell together with Satoshi Ōmura "for their dis-
coveries concerning a novel therapy against roundworm
infections" (Fig. 1). These parasitic infections have en-
dangered human existence disproportionately, impeding
productivity and economic growth due to major public
health and societal burdens in developing and semi-
industrialized countries in Sub-Saharan Africa, South-
east Asia and South America [1, 2]., For example, approxi-
mately 25 million people in Africa are still infected by
onchocerciasis with more than 300,000 suffering from
blindness, which explains the disease's alternative name
'river blindness'. It is estimated that the population at risk
of just this one disease in the 31 endemic countries will be
250 million by 2016 [2, 3].
The burden of persisting and threatening infectious
diseases in most developing countries is a complex affair,
a fact recognized by The United Nations' Millennium
Development Goals (MDGs) [4] that represent one of
the most successful anti-poverty movements ever under-
taken. This 15-year effort to achieve eight goals, set out
in the Millennium Declaration of the year 2000, has pro-
vided invaluable insights how governments, business and
civil society can work together and achieve transform-
ational breakthroughs in many areas, not the least in
dealing with long-term, endemic diseases. Ours is a pivotal
time for the international development sector with
massive implications for global co-operation to control
and eliminate endemic diseases and promote transforma-
tive social change to end poverty. The new 17 Sustainable
Development Goals (SDGs) constitute a continuation and
expansion of all aspects of the original eight MDGs and
inclusion of neglected tropical disease (NTDs) in the Sus-
tainable Development Goals. With respect to health, the
MDG goal number 6 (to combat HIV/AIDS, malaria and
other diseases) has been replaced by the SDG goal number
3 (to ensure healthy lives and promote well-being for all at
all ages). Goal number one remains the same, i.e. to end
poverty everywhere.
The root cause of the infectious diseases of poverty
(IDoPs) is the ubiquitous presence of infectious agents.
However, social and economic issues play a large role in
their transmission and persistence, a fact recognized in
both the MDGs and the follow-up SDGs. Still, the trans-
formation of the endemic landscape is almost entirely
due to large-scale distribution of the three novel 'wonder
drugs' artemisinin, ivermectin and praziquantel, mainly
used against malaria, lymphatic filariasis (LF)/river
blindness and schistosomiasis, respectively. All three,
discovered and developed in the 1970s (though extracts
of the plant Artemisia - qinghaosu - has a long history
in Chinese traditional medicine), are broad-spectrum
drugs that can be used to cure many more infections
than mentioned above; amazingly, the artemisinins have
even effect against immature schistosomes, while iver-
mectin seems to limit the behaviour of the malaria vec-
tor. However, it was not evident that a new era had
begun until the new drugs were in general use. Trying to
pinpoint this historic shift exactly is of course futile, but
Fig. 1 Nobel Prize Laureate Scientists in Physiology or Medicine, 2015
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it can be said that after the large-scale introduction of
modern chemotherapy in the 1980s and 1990s, the first
decade of the new millennium marks the time that
world-wide implementation of mass drug administration
(MDA) occurred [9, 12]. Thanks to market price reduc-
tions and broad-scale interventions by international
donor programmes, it did not take long until major en-
demic diseases had become manageable. Indeed, disease
control programmes in the endemic countries were not
only showing clear progress, but it was also possible to
sustain the reduced morbidity and mortality achieved
making it realistic to start planning for elimination of
many of the endemic IDoPs, a momentous revolution
[10, 12].
The discovery of artemisinin and ivermectin have had,
and will continue to have, a long-lasting, strong impact
on the IDoPs, the former due to its effect on the para-
sites causing malaria; the latter because its effect on the
different nematodes that cause river blindness (Oncho-
cerca volvulus), LF (Brugia and Wuchereria), hookworm
infection (Ancylostoma, Necator) and other soil-
transmitted helminthic (STH) infections [1–4]. With the
presentation of a road map for the battle against the
NTDs in January 2012, the World Health Organization
(WHO) inspired the international community to engage
into coordinated action involving policy-makers and im-
plementers as well as international donors and the
pharmaceutical industry [4]. While it was evident that
many of these diseases could realistically be targeted for
elimination, it was equally clear that novel drugs, sensi-
tive diagnostics and sustainable approaches for effective
surveillance and response together with effective and co-
ordinated, preventive vector control programmes also
must be in place [5, 6]. The new drugs, already devel-
oped, licensed and used for public health , have de-
cisively demonstrated that malaria, river blindness and
LF are preventable diseases whose control would par-
ticularly benefit the most vulnerable sectors of the en-
demic populations [4–8]. Progress has been achieved in
all these areas, but greatest impact so far has been with
respect to chemotherapy rather than vaccines that will
be needed to complement chemotherapy in the longer
perspective [7–10].
Youyou Tu's landmark work, documented by increas-
ing access to life-saving, effective artemisinin-based
combination therapies (ACTs) against acute and severe
malaria, intermittent preventive treatment and curative
with respect also to the asexual plasmodium stages, has
provided relief and hope for a large proportion of vul-
nerable populations in the endemic areas [9–11]. Im-
portantly, in the face of increasing resistance of malaria
parasites to 4-aminoquinolines (chloroquine) and antifo-
late drugs (sulphadoxine-pyrimethamine), thanks to the
advent of the ACTs that the Global Malaria Action Plan
(GMAP) managed to reduce malaria morbidity and mor-
tality by 75 per cent in comparison to the situation in
2005, particularly among the poorest groups across all
affected countries aggregately [12, 13]. Moreover, the
new chemotherapy approach has made it possible to
scale up national malaria control and elimination pro-
grammes enhancing interventions and universal health
coverage to achieve WHO's Roll Back Malaria (RBM)
initiatives and those of the MDGs [13, 14]. For example,
by the end of 2012, the United Nations Children's Fund
(UNICEF) had procured about 25 million ACTs treat-
ments for 28 countries; however the proportion of chil-
dren in sub-Saharan Africa with access to ACT is still
variable and in many cases despairingly low (range <7 %
to >90 % with the latter level only reached in a few
countries) [10, 15, 16]. ACT is the drug of choice against
acute and severe infection by Plasmodium falciparum
and P. vivax, the most deadly malaria species, which are
now resistant to chloroquine and antifolate drugs
[10, 11, 16] in most endemic areas. Hence the call for
innovative and integrated community-based packages
[16, 17] in strengthening implementation and manage-
ment has executed by the Malaria Eradication Research
Agenda (malERA) and the Malaria Eradication Scientific
Alliance (MESA) in the most highly endemic developing
and semi-industrialized countries [18].
Both acute and severe malaria continues to exert a
deep-rooted impact in 109 countries and territories
around the world and still constitute a leading risk factor
for infant mortality and sub-optimal growth and devel-
opment in spite of the global malaria elimination cam-
paign programmes (GMECPs) that were in effect in the
1950s to the 1970s [10, 19]. By 2000, there was an esti-
mated 350–500 million cases of malaria and more than
one million deaths, most of them in children under
5 years, pregnant women and non-immune travelers in
Africa and Asia-Pacific [19]. The saying “One child
dying of malaria every second” remains true to this day,
and the disease still has a serious economic impact in
Africa, retarding economic growth and development and
perpetuating the vicious cycle of poverty [15, 18–20].
In 1971, at the Pharmaceutical Institute of the Academy
of Traditional Chinese Medicine, Youyou Tu showed that
Artemisia plant extracts could kill P. berghei, a rodent
malaria parasite laboratory model. The following year, she
succeeded in isolating the active ingredient (qinghaosu),
now part of ACT, the most important class of anti-malaria
medications [9, 20, 21]. Artermisinin derivatives are postu-
lated to act by inhibiting the major metabolic processes of
the malaria parasite, such as glycolysis, nucleic acid and
protein synthesis, thus exercising a broad- based activity
extending to impeding the development of gametocytes
that promises future development of transmission-
blocking, sexual-stage drugs and vaccine discovery
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[5, 6, 11, 15, 22, 23]. Still, years after the original discovery
of the drug, the complete mechanism of artemisinin is not
fully elucidated, though recent evidence suggest that is
based on the activity of 13 proteins, some of which shown
to be involved in the emergence of resistance in Southeast
Asia, e.g. the Thai-Cambodia borders areas [24]. Impres-
sive progress has been achieved in product development,
manufacturing, procurement as well as financial accessi-
bility to treatment (the latter regarding the ACTs in
particular) even if prompt, affordable and widespread
coverage is still not achieved in many public health
facilities in remote, hard-to-reach endemic settings
[12, 24, 25]. From 2004 to 2006, the annual global
procurement of ACT increased from 4 million to ~100
million doses (~125 million doses in 2007), around 70 %
of which were used in Africa, resulting in a significant
reduction of morbidity and mortality in children and
trimmed-down numbers of acute and severe cases of
malaria overall [12, 14, 25, 26].
The latest decades have witnessed substantial pro-
gress in raising awareness and increasing the produc-
tion, adoption and distribution of existing effective
interventions besides the use of ACTs, e.g. indoor
residual spraying (IRS) and large-scale distribution of
long-lasting insecticidal nets (LLINs) as prescribed by
the RBM's universal coverage partnership [12, 27, 28].
The latest available worldwide report of malaria cases
concerns the year 2013, in which WHO reports that
about 3.2 billion people are at risk of this infection
with more than 132 million confirmed cases; however,
the real level of incidence must be higher since the
number of suspected cases has surpassed 367 million
[29]. Africa still has the heaviest burden with children
less than 5 years old making up 90 % of the malaria-
related deaths, which accounts for 78 % of the total
mortality [29, 30]. In addition to the high local
healthcare burden in Africa, malaria illness and mor-
tality affect crop production and decrease tourism,
which is estimated to cost approximately USD12
billion each year due to increased school and work
absenteeism, lost productivity and constraints to
foreign investment [10, 30]. Hence, although the im-
pact of malaria in the endemic countries has abated
to some extent in some areas, transmission continues
at a high level assuring that the global ACTs demand
will remain robust over the coming years as
treatment-adherence and compliance remain vital in
the struggle to substantially reduce malaria morbidity
and mortality supporting the hope of eventually
reaching sustained control, elimination and subse-
quent eradication of the disease [29, 31].
William C. Campbell and Satoshi Ōmura discoveries
proved to be a breakthrough in the tenacious fight
against infections caused by roundworm parasites,
mainly onchocerciasis and LF, dreaded health scourges
of the most vulnerable groups of affected populations.
The discovery, industrial development and implementa-
tion of the active avermectin derivative ivermectin (best
known under the brand name Mectizan) led to a signifi-
cant reduction of onchocerciasis in the endemic areas in
central Africa and Latin America as well as of LF and
scabies that are also endemic in India and Southeast
Asia, thus improving the situation in vulnerable commu-
nities in low- and middle-income countries (LIMCs) [1,
3]. In an unusual move, the manufacturer of ivermectin,
Merck & Co., Inc. declared it would donate ivermectin
free of charge for as long as it would be needed through
its Mectizan Donation Program, which works with gov-
ernments (Ministries of Health) and various partners
with national onchocerciasis control programmes to
scale up distribution and coverage of the drug locally
[9, 32]. Its impact on mosquitoe control in malaria is
debatable and the drug is not donated for this
purpose.
Onchocerciasis, transmitted by the filarial worm O.
volvulus, is transmitted to humans through bites of in-
fected female blackflies (Simulium spp.). Adult worms
can live up to 18 years in infected human hosts and re-
lease up to 1,000 microfilariae daily causing a variety of
ailments including skin lesions due to chronic derma-
titis, , rashes, intense itching, depigmentation as well as
visual impairment due to eye inflammation causing
corneal scars eventually leading to irreversible blind-
ness [3, 32]. The disease is endemic in 35 countries,
including 28 African countries, Yemen in the Middle
East and six Latin American countries resulting in an
estimated 17.7 million people infected, approximately
500,000 with visual impairment, 270,000 of whom are
blind; about 99 % of all cases, however, are found in
Africa according to WHO [2, 32, 33]. The Onchocer-
ciasis Control Programme (OCP) operated in West
Africa from 1974 to 2002 [2–33] and its work is be-
ing continued by the larger African Programme for
Onchocerciasis Control (APOC) that coordinates
annual community-wide treatment regimens with
ivermectin in 16 countries. An estimated 8.2 million
disability-adjusted life years (DALYs) [4, 13] at a nominal
cost of about USD257 million was averted between 1995
and 2010 and APOC estimates to have warded off another
9.2 million DALYs between 2011 and 2015 at a nominal
cost of USD 221 million [2, 4]. Interventions in countries
in West Africa employed large-scale, community-directed
treatment with ivermectin (CDTI) and ONCHOSIM, a
computer-based software developed to model the trans-
mission and control of onchocerciasis allowing the con-
tinuous annual treatment of more than 30 million people
[34]. As of 2012, over 200 million people have received
ivermectin; 118 million a combination of ivermectin and
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albendazole and more than 100 million people have been
treated in 26 countries in 2013 alone [35].
The Onchocerciasis Elimination Program of the
Americas (OEPA) was launched in 1992 under the Pan
American Health Organization (PAHO) with the goal of
interrupting onchocerciasis transmission in six endemic
Latin American countries by 2015 [36]. The WHO's
regional NTDs elimination agenda includes fostering
coalition and partnerships in resource mobilization
aimed at increasing free availability and accessibility of
ivermectin to needy populations. Since 2007, WHO also
engaged in activities ensuring periodic sustainability of
treatment activities and feasibility studies of foci and
ongoing regional eradication [36, 37]. Columbia became
the first country achieving elimination of onchocercia-
sis; Ecuador and Mexico have also been verified as free
from transmission (verified by WHO in 2013). Likewise,
Brazil and the Bolivarian Republic of Venezuela have
embarked on reciprocal, cross-border interventions find-
ing ivermectin very effective in controlling the disease
[36–38]. Ivermectin is provided as MDA once or twice
annually to millions of the most vulnerable children
and adults populations in most LMICs [3, 4, 39, 40].
Interruption of transmission of O. volvulus and reduc-
tion of the burden of visual impairment and blindness
have been achieved [41, 42]. However, repeated iver-
mectin treatment showed reduced susceptibility in the
India and South East Asia LF control to elimination
programmes. This has led to the call for novel alterna-
tive approaches in accelerating and sustaining the
transmission-free status once achieved to avoid the
risk for re-introduction or resistance of the disease in
the process of elimination and eventual eradication in
Africa and others areas (e.g.: Yemen) with disease co-
endemicity [33, 35, 43].
Though not recognized for this year's Nobel Prize, the
story would not be complete without mentioning prazi-
quantel. Praziquantel, a drug that has modernized the
control of schistosomiasis and many other helminth in-
fections in the same way the ACTs and ivermectin
worked for malaria and LF/onchocerciasis, respectively
[44, 45]. Praziquantel was developed by the German
pharmaceutical companies Merck KGaA, Darmstadt and
Bayer AG, Leverkusen in the early 1970s [46–48] and
the drug currently figures on WHO's list of essential
medicines [49]. The drug’s good safety profile and broad
therapeutic efficacy extend its therapeutic efficacy from
the five Schistosoma spp. species capable of infecting
humans [47, 50–52] to cestodes (tapeworms) such as
Echinococcus spp. [49], whose larval stages infects vari-
ous organs, Taenia spp. that can infect the brain and
muscles with its eggs and larvae (cystocercosis) and
food-borne trematodes (FBTs), such as Paragonimus
spp., Opistorchis spp. and Clonorchis spp. [50].
FBT transmission is linked to traditional customs, e.g.
consumption of dishes containing raw fish, crustaceans
and plants in countries where these diseases are sus-
tained by entrenched cultural practices, which are diffi-
cult to change. FBTs affect over 56 million people
infected in over 70 countries [51]; this figure, however,
includes Fasciola spp., a parasitic worm preferably
treated with triclabendazole (sold under trade names
Egaten and Fasinex) [52].
Schistosomiasis is acquired through contact with water
infested with cercariae, the free-swimming larval forms
emanating from the intermediate snail host when
infected. The microscopic adult worms live in the veins
of abdominal organs, where large amounts of eggs are
produced for excretion via faces or urine aimed at hatch-
ing and infecting fresh-water snails thus closing the
parasite's lifecycle. Large numbers of the eggs are, how-
ever, trapped in the tissues and where immune reactions
cause damage that varies from subtle to serious. Millions
of people suffer from severe schistosomiasis [2, 44, 53], a
type of injury that can be suppressed by regular treat-
ment preventing reinfection giving rise to morbidity.
The current WHO chemotherapy-based strategy con-
trols the morbidity in poor and marginalized communi-
ties in conjunction with interventions against cestode
and nematode infections with albendazole and ivermec-
tin. Severe morbidity due to schistosomiasis can be
prevented by regular treatment of risk groups targeted
based on community diagnosis at sentinel sites. Like
malaria, LF and river blindness, schistosomiasis is preva-
lent in tropical and sub-tropical areas, in poor commu-
nities without potable water and adequate sanitation.
Like the other infections discussed here, schistosomiasis
is one of IDoPs. It affects about 240 million people
worldwide, and more than 700 million people live in
endemic areas [53, 54]. In contrast to FBT infections,
cysticercosis and echinococcosis, there has been strong
progress on the schistosomiasis agenda, mainly thanks
to long-term, national control programmes that in some
countries, notably Brazil, China and Egypt, have been
highly successful in driving prevalence and morbidity
down. In 2013, more than 39 million people were
treated for this disease with praziquantel. However, this
represents only about 13 % of the population requiring
treatment globally [2, 44, 46, 55, 56].
The global IDoP elimination agenda will require strength-
ening community, national and regional leadership and
commitment to rapidly increase funding and fostering
integrated multidisciplinary and inter-sectorial policies.
Furthermore, scaling-up of high-impact MDA coverage of
available drugs, development and implementation of new,
effective vaccines and other novel approaches and tools are
needed in addressing the geographical complexity of the
panoply of different diseases including malaria, river
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blindness, LF and schistosomiasis [56, 57]. This would
mean enlarging the use of geographical information sys-
tems (GIS) and other advanced cutting-edge technologies
for general surveillance and monitoring, including risk
mapping of vector and parasite hotspots and studying res-
ervoir resurgence and drug resistance. Improving local
and cross-border malaria early-warning signals and sur-
veillance systems is imperative in providing new informa-
tion on potential epidemiologic transitions, crucial for
quick response to any potential resurgence of vector dens-
ity and competence potentially leading to disease outbreaks.
These approaches will contribute to new evidence-based in-
formation needed in adapting effective health financing and
programming to effective local and national programmes
and interventions. Hence, consolidating and refining the
laudable gains and lessons learnt from cost-effective thera-
peutic discoveries should contribute to the continuous
pharmacovigilance associated with adverse reactions (ADR)
of existing therapies leading to improved access to quality
care services, procurement and supply of quality medicines
and supplies needed in boosting the momentum of the
elimination of IDoP.
The pharmacological and therapeutic paradigm shift
discussed here calls for further, strong investments in re-
search and development in the field of drugs and vac-
cines creating pipelines of new products capable of
tackling the challenge of rapid emergence and spread of
vectors, parasites and drug resistance. Timely, evidence-
based and cost-effective operational approaches and so-
lutions for IDoPs and NTDs are required for dealing
with the rise and spread of insecticide resistance, and
the environmental impact of climate change. Likewise,
development of diagnostics with improved sensitivity
and specificity as well as preventive therapeutics and ef-
ficient information communication/dissemination mech-
anisms underscore the quest for novel and innovative
approaches. Leveraging on lessons learnt, efficient and
integrated intersectoral partnerships as well as collabor-
ation in the development of needed, new diagnostics,
drugs and vaccines are much needed. So are also proven
and innovative community-based programmes with re-
spect to ownership in health systems, surveillance and
new opportunities in elimination interventions packages
and eventually in moving forward eradication of IDoP
worldwide.
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